Dermatology News and Research

Latest Dermatology News and Research

Sangretech Biomedical signs amended license agreement with Bostwick Laboratories

Sangretech Biomedical LLC, a developer of dendritic cell therapies for cancer and infectious diseases, today announced it has executed an amended and restated license agreement with Bostwick Laboratories, Inc. providing Bostwick Scientific, the research division of Bostwick Laboratories, with exclusive rights to Sangretech’s dendritic cell technology in certain territories.

15 Oct 2009

National Biological to market Quantel's 308 Excimer System in the U.S.

Quantel SA (Euronext: QUA), a leading manufacturer of solid state lasers, announced today that it has entered into a Distribution Agreement with National Biological, a leading researcher and developer of light-based systems for medical and cosmetic treatments, for Quantel's 308 Excimer System for monochromatic UVB treatment of psoriasis and vitiligo in the United States.

15 Oct 2009

More than half RCTs do not report vital information about study populations race, says study

A new study recently published online by the American Heart Journal shows that more than half of all randomized clinical trials, or RCTs, for cardiovascular disease are not reporting vital information about the study populations race or ethnicity. NYU School of Medicine researchers found that out of the 156 cardiovascular disease RCTs analyzed, only 35% of trials reported any information on race or ethnicity between 1970 and 2006. From 2000 to 2006, 46% of trials included that information.

15 Oct 2009

APN and Cardinal Health sign agreement to help improve practice operations

Aesyntix Physician Network (APN), a leading national group purchasing organization (GPO) for dermatologists and plastic surgeons, today announced it has signed an agreement with Cardinal Health to provide APN members with products and services designed specifically for dermatologists and plastic surgeons.

15 Oct 2009

Provectus Pharmaceuticals commences compassionate use program of PV-10 for cancer

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has expanded its compassionate use program for PV-10, making the agent, which is being developed as a therapeutic agent for a broad spectrum of cancers, available for select cancer patients in the United States. The program is already in progress in Australia, where it was initiated in June 2009.

14 Oct 2009

NanoBio to receive a $4.1M subcontract for developing nanoemulsion-based mucosal vaccine adjuvants

NanoBio Corporation today announced an award from the National Institute of Allergy and Infectious Diseases, a Division of The National Institute of Health, to fund vaccine research associated with “Innate Immune Receptors and Adjuvant Discovery.” NanoBio is the principal subcontractor for the $9.3 million contract awarded to the University of Michigan.

14 Oct 2009

Systagenix Wound Management forms new global Medical Advisory Board

Systagenix Wound Management has announced the formation of a new global Medical Advisory Board, consisting of a group of multi-disciplinary and highly respected wound care clinicians and practitioners from North America and Europe, which will be led by Systagenix's newly appointed Medical Director, Dr Robert Snyder.

13 Oct 2009

Provectus Pharmaceuticals completes initial treatment in Phase 2 trial of PH-10 for plaque psoriasis

Provectus Pharmaceuticals, Inc., a development stage oncology and dermatology biopharmaceutical company, has completed patient accrual and initial treatment in its Phase 2 trial of PH-10 for the treatment of plaque psoriasis. This milestone marks the third Phase 2 clinical trial for which Provectus has completed patient accrual since May 2009.

13 Oct 2009

Psoriasis patients taking immunosuppressive drugs at increased risk of H1N1 flu viruses

People with psoriasis and/or psoriatic arthritis who are taking biologic or non-biologic immunosuppressive medications should receive the inactived forms of both seasonal influenza and H1N1 (swine flu) vaccines as soon as possible, according to a recommendation from the National Psoriasis Foundation.

13 Oct 2009

Halozyme Therapeutics to host a meeting for analysts and investors

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that it will host a meeting for analysts and investors on October 15 in New York.

8 Oct 2009

MDLiveCare and Google Health collaborate to provide online health record platform

MDLiveCare, an on-demand telehealth company, announced today at the Health2.0 conference in San Francisco a partnership with Google Health.

8 Oct 2009

The CE Marked HairDX Genetic Test for Hair Loss launched in Europe

The HairDX Genetic Test for Hair Loss, the world’s first genetic baldness (Androgenetic Alopecia) test, is now available as a CE Marked product under the European In Vitro Diagnostic Directive.

8 Oct 2009

NEI awards Case Western Reserve $1.57M for bacterial keratitis research

Researchers at Case Western Reserve University School of Medicine have been awarded a $1.57 million renewal grant from the National Eye Institute (NEI) of the National Institutes of Health to continue their study of corneal infections, specifically, bacterial keratitis, associated with contact lens wear. The grant will extend the work initiated last year with the receipt of a $2.4 million, five-year grant from the NEI.

8 Oct 2009

Merz publishes Phase III study results assessing the impact of NT 201 on muscle tone

Data results published this month in Clinical Neuropharmacology, revealed that Merz Pharmaceuticals' NT 201 (botulinum toxin type A free from complexing proteins), also known by the brand name Xeomin in Europe and Canada, was statistically significantly more efficacious than placebo for the treatment of patients with post-stroke upper limb spasticity.

7 Oct 2009

940nm wavelength laser is superior for treating facial spider veins: BUSM researchers

Researchers from Boston University School of Medicine (BUSM) have concluded that the 940nm wavelength laser is superior for treating facial spider veins (telangiectasias) as compared to the 532nm wavelength laser. The findings, which appear in the recent issue of Lasers in Surgery and Medicine, are the first time these lasers were tested against each other for superiority.

7 Oct 2009

Early Phase II clinical trial for RK-023 to treat androgenetic alopecia

R-Tech Ueno, Ltd. has started early Phase II clinical trial for RK-023, a physiologically active fatty acid derivative developed by the company -- a new compound targeted as a treatment for androgenetic alopecia (male pattern baldness).

7 Oct 2009

Researchers find increase in the number of procedures performed for dermatologic health care

Researchers from Boston University School of Medicine (BUSM) and the Laser and Skin Cancer Center of Indiana, (Carmel, Indiana), found that there has been a dramatic increase in the number of procedures performed and patient demand for dermatologic health care since 2000. The findings, which were recently reported in Dermatologic Surgery, parallels the growth in the age of individuals between the ages of 40 to 55, who make up the "Baby Boomer" generation.

6 Oct 2009

Winner of 2009 NAMS award

Michael Holick, PhD, MD, director of the Bone Healthcare Clinic and the Vitamin D, Skin and Bone Research Laboratory at Boston University School of Medicine BUSM recently received the 2009 NAMS/Upsher-Smith Laboratories, Inc.Vitamin D Research Award from the North American Menopause Society (NAMS).

6 Oct 2009

LA BioMed granted $1.3M for investigating ESAI's KRONOS IV in correcting erectile dysfunction

Las Vegas-based Endogenous Stem Cells Activators Inc. (ESAI) announced today that it will award a $1.3 million grant to Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LABioMed) for pre-clinical studies aimed at activating penile endogenous (adult) stem cells with the company's drug, KRONOS IV.

5 Oct 2009

Baxter launches HYLENEX recombinant for pediatric rehydration at the 2009 ACEP

Baxter International Inc. today announced the commercial launch of HYLENEX recombinant (hyaluronidase human injection) for use in pediatric rehydration at the 2009 American College of Emergency Physicians (ACEP) scientific assembly (Boston). HYLENEX, an enzyme, allows fluids to be administered under the skin (subcutaneously) rather than through a vein.

From Baxter International Inc. 5 Oct 2009

Dermatology News and Research

Latest Dermatology News and Research

Sangretech Biomedical signs amended license agreement with Bostwick Laboratories

National Biological to market Quantel's 308 Excimer System in the U.S.

More than half RCTs do not report vital information about study populations race, says study

APN and Cardinal Health sign agreement to help improve practice operations

Provectus Pharmaceuticals commences compassionate use program of PV-10 for cancer

NanoBio to receive a $4.1M subcontract for developing nanoemulsion-based mucosal vaccine adjuvants

Systagenix Wound Management forms new global Medical Advisory Board

Provectus Pharmaceuticals completes initial treatment in Phase 2 trial of PH-10 for plaque psoriasis

Psoriasis patients taking immunosuppressive drugs at increased risk of H1N1 flu viruses

Halozyme Therapeutics to host a meeting for analysts and investors

MDLiveCare and Google Health collaborate to provide online health record platform

The CE Marked HairDX Genetic Test for Hair Loss launched in Europe

NEI awards Case Western Reserve $1.57M for bacterial keratitis research

Merz publishes Phase III study results assessing the impact of NT 201 on muscle tone

940nm wavelength laser is superior for treating facial spider veins: BUSM researchers

Early Phase II clinical trial for RK-023 to treat androgenetic alopecia

Researchers find increase in the number of procedures performed for dermatologic health care

Winner of 2009 NAMS award

LA BioMed granted $1.3M for investigating ESAI's KRONOS IV in correcting erectile dysfunction

Baxter launches HYLENEX recombinant for pediatric rehydration at the 2009 ACEP

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Dermatology News and Research

Latest Dermatology News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in